Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 254
- 试验地点
- 1
- 主要终点
- Organisms detected with their antibiotics sensitivity
研究概览
简要总结
Spontaneous bacterial peritonitis (SBP) is a serious complication in cirrhotic patients, and the changes in the microbiological characteristics reported in the last years are impacting the choice of antibiotic used in the treatment. Cefotaxime has been the most extensively studied antibiotic for this infection. It is considered to be one of the first choice antibiotics because of low toxicity and excellent efficacy. Treatment of SBP by intravenous cefotaxime should be administered for a minimum 5 days. Antibiotic-resistant microorganisms have been increasingly reported especially to cefotaxime and its effect on the clinical outcome in treating SBP.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with liver cirrhosis and ascites and clinical findings suspicious of ascitic fluid infection
排除标准
- •Patients were excluded if they received antibiotics ten days prior to the hospital admission or there is evidence of secondary bacterial peritonitis, tuberculous peritonitis, malignant ascites or ascites due to other causes e.g. cardiac or renal diseases
研究组 & 干预措施
CNNA-group 2
Culture negative neutrocytic ascites
干预措施: Cefotaxime (Drug)
MNBA-group 3
monomicrobial non-neutrocytic ascites
干预措施: Cefotaxime (Drug)
SBP-group 1
Spontanous bacterial peritonitis
干预措施: Cefotaxime (Drug)
结局指标
主要结局
Organisms detected with their antibiotics sensitivity
时间窗: 8 months
次要结局
未报告次要终点
研究者
Dr Ahmed Ali Elbaz
Dr
Nasser Institute For Research and Treatment